BRAF and melanoma: Drug holidays reduced melanoma cells resistant to the BRAF inhibitor vemurafenib but the underlying biochemical causes have remained elusive.43 In our models of PI3Ki resistance, drug withdrawal caused a proliferative defect that, interestingly, was associated with the appearance of a metabolic phenotype characterized by increased respiratory and glycolytic activities (Figure 1).